Tuesday, 29 September 2020

Glenmark receives ANDA approval for Clobetasol Propionate Foam

18 February 2019 | News

It is a generic version of Olux®1 Foam, 0.05%, of Mylan Pharmaceuticals

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05%, a generic version of Olux®1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc.

According to IQVIATM sales data for the 12 month period ending December 2018, the Olux® Foam, 0.05% market2 achieved annual sales of approximately $50.9 million.

Glenmark’s current portfolio consists of 150 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account